Literature DB >> 4125239

5-Azacytidine: a new active agent for the treatment of acute leukemia.

M Karon, L Sieger, S Leimbrock, J Z Finklestein, M E Nesbit, J J Swaney.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4125239

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  21 in total

Review 1.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

Review 2.  Leukaemogenesis: more than mutant genes.

Authors:  Jianjun Chen; Olatoyosi Odenike; Janet D Rowley
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

3.  Cell cycle effects and cellular pharmacology of 5-aza-2'-deoxycytidine.

Authors:  R L Momparler; J Samson; L F Momparler; G E Rivard
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia.

Authors:  A T Look; G V Dahl; G Rivera; A M Mauer
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  Cellular metabolism of 5,6-dihydro-5-azacytidine and its incorporation into DNA and RNA of human lymphoid cells CEM/O and CEM/dCk(-).

Authors:  V I Avramis; W C Powell; R A Mecum
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Enhanced in Vitro Anti-Tumor Activity of 5-Azacytidine by Entrapment into Solid Lipid Nanoparticles.

Authors:  Farhad Jahanfar; Akbar Hasani; Dariush Shanebandi; Mohammad Rahmati; Hamed Hamishehkar
Journal:  Adv Pharm Bull       Date:  2016-09-25

Review 7.  Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.

Authors:  Giuseppe Leone; Francesco D'Alò; Giuseppe Zardo; Maria Teresa Voso; Clara Nervi
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

8.  Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine.

Authors:  Steven E McCormack; Erica D Warlick
Journal:  Onco Targets Ther       Date:  2010-09-07       Impact factor: 4.147

9.  Depression of experimental gastric ulcers and acute pancreatitis in rats treated by 5-azacytosine, 5-azacytidine and their N-methyl derivatives.

Authors:  A Cihák; A Pískala; L Korbová; J Cízková; V Kucerová
Journal:  Experientia       Date:  1986-01-15

10.  5-Azacytidine and RNA secondary structure increase the retrovirus mutation rate.

Authors:  V K Pathak; H M Temin
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.